Theravance Biopharma Inc. – Underwriting Agreements

NASDAQ: TBPH
Share price (5/22/26): $16.37
Market cap (5/22/26): $844 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Underwriting Agreements Filter

from SC 13G ~1 page Joint Filing Agreement

from 8-K 44 pages Theravance Biopharma, Inc. (A Cayman Islands Exempted Company) 6,700,000 Ordinary Shares, Par Value $0.00001 Per Share Underwriting Agreement

from 8-K 43 pages Theravance Biopharma, Inc. (A Cayman Islands Exempted Company) 5,500,000 Ordinary Shares, Par Value $0.00001 Per Share Underwriting Agreement

from S-3ASR 36 pages Theravance Biopharma, Inc. $150,000,000 Ordinary Shares Sales Agreement

from 8-K 33 pages Note Purchase Agreement Dated November 30, 2018 Among Theravance Biopharma R&D, Inc., Triple Royalty Sub LLC and the Purchaser Named Herein $250,000,000 Triple Pharmasm 9.0% Fixed Rate Term Notes Due 2033

from 8-K 42 pages Theravance Biopharma, Inc. (A Cayman Islands Exempted Company) $200,000,000 3.250% Convertible Senior Notes Due 2023 Underwriting Agreement October 27, 2016

from 8-K 41 pages Theravance Biopharma, Inc. (A Cayman Islands Exempted Company) 3,850,000 Ordinary Shares Underwriting Agreement

from 8-K 40 pages Theravance Biopharma, Inc. (A Cayman Islands Exempted Company) 4,765,000 Ordinary Shares Underwriting Agreement April 28, 2016

from S-3 42 pages Theravance Biopharma, Inc. Ordinary Shares (Par Value $0.00001 Per Share) Controlled Equity Offeringsm Sales Agreement